Novo Nordisk’s heart drug ziltivekimab failed in its biggest trial, showing no real benefit in preventing heart attacks, strokes, or death despite reducing inflammation — and even raising infection risks. The setback crushed stock prices, though two other trials for heart failure and post-heart attack patients are still ongoing, with results expected by 2027. A reminder: great science doesn’t always translate to clinical success.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
